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Abstract
Staphylococcus aureus is one of the most successful opportunistic pathogen able to cause 
serious infections due to its ability to produce virulence factors and acquire antimicro-
bial resistance. Recent reports indicate that the phenotypic changes in the cell wall and 
cell membrane are essential mechanisms related to the resistance to several antibacterial 
drugs (such as daptomycin and vancomycin). These alterations involve changes in cell 
wall composition and chemical modifications of some components (point mutation lead-
ing to modification in phosphatidylglycerol molecule, in the production of the aberrations 
in peptidoglycan structure and decrease in autolytic activity of the components of the 
cell envelope), leading to changes in electric charge of the cell surface, cell membrane 
fluidity and cell morphology. In fact, S. aureus develops several multifactorial and strain-
specific adaptive mechanisms to survival in host. The study of such mechanisms is very 
important. The aim of this chapter is to review the phenotypic mechanisms related to drug 
resistance in S. aureus.
Keywords: Staphylococcus aureus, daptomycin, vancomycin, heteroresistance, stress 
stimulon response
1. Introduction
The lipopeptide and glycopeptide antibiotics are very effective against infections caused by 
Gram-positive cocci, showing good efficacy against Staphylococcus aureus. The mechanism of 
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action of these antibiotics is linked with their ability to block cell wall bacterial synthesis. As 
examples of the most used drugs to treat S. aureus infection, we have daptomycin (DAP) and 
vancomycin. However, currently, the indiscriminate use of these antimicrobials has decreased 
their effectiveness against S. aureus strains [1].
Daptomycin (DAP) is a cyclic lipopeptide antibiotic obtained from Streptomyces roseosporus 
with activity against the most Gram-positive bacteria, including vancomycin-resistant entero-
cocci (VRE) and methicillin-resistant S. aureus (MRSA) [2–4]. DAP appears to have multiple 
effects on the Gram-positive bacterial cell membrane (BCM) [5]. The mechanism of action 
proposed is the aggregation between DAP and BMC, which alters the architecture of cell 
membrane and forms pores, leading to ion loss. This new arrangement leads to a rapid depo-
larization, resulting in a loss of membrane potential that culminates in bacterial cell death. 
Regarding the interaction mechanisms with the formation of cell wall and surface, a special 
mention should be given to the interference in peptidoglycan and lipoteichoic biosynthesis 
[6–8].
The glycopeptide antibiotics were introduced in therapy against infections caused by S. aureus 
in 1955 [9]. The vancomycin is glycopeptide produced by Amycolatopsis orientalis (actinomy-
cete) and is the representative of this class of antibiotic widely used in medical practice today, 
especially after the appearance of resistant strains of S. aureus to methicillin [10]. However, the 
emergence of molecular mechanisms of resistance to vancomycin and the appearance of phe-
notypic resistance profiles in heterogeneous subpopulations of S. aureus as described suscepti-
ble have hindered the use of glycopeptide as first choice agent in antibiotic therapy [11]. Some 
reduced susceptibility phenotypes are classified in some profiles as vancomycin-intermediate 
S. aureus (VISA) and vancomycin-resistant S. aureus (VRSA) [11]. Subpopulations of hetero-
geneous S. aureus with heterogeneous resistance to vancomycin and notoriously sensitive to 
vancomycin are classified as heteroresistant vancomycin-intermediate S. aureus (hVISA) [1].
Heteroresistance is defined as resistance to antibiotics expressed by a subset of a microbial 
population that initially is considered susceptible to these antibiotics. These resistant subpopu-
lations are able to adapt to increasing drug concentrations in a stepwise manner [12]. This 
phenomenon has been described in a wide range of bacteria and fungi, but attention has been 
directed toward S. aureus [13]. For the S. aureus hVISA strains containing subpopulations of 
vancomycin-intermediate daughter cells, the minimal inhibitory concentrations (MICs) for the 
parent strains of these daughter cells fall within the susceptible range of 1–4 μg/mL. However, 
if the lineage is exposed to increasing concentrations of vancomycin, a new generation of cells 
with reduced susceptibility profiles will be favored. This exhibition creates a selective pres-
sure that favors the outgrowth of rare vancomycin-resistant clones leading to hVISA clones. 
Eventually, the continued exposure to vancomycin culminates in a uniform population of 
VISA phenotypes [14]. Evidence in clinical case studies which monitored S. aureus infections in 
250 patients showed that the hVISA phenotype is closely related with significantly prolonged 
bacteremia events and associated with increased rates of endocarditis and osteomyelitis, com-
pared with methicillin-resistant Staphylococcus aureus (MRSA) bacteremia [15].
VISA and hVISA have an increased D-Ala-D-Ala moieties in their thickness cell wall that form 
false targets that sequester vancomycin, with reduced autolytic activity and slow growth in 
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vitro ([14]. This phenomenon is believed to “trap” vancomycin and this, together with the 
thickened cell wall, may act as a barrier to the diffusion of large molecules, like daptomycin 
(as cited below) [16, 17]. In this way, the emergence of these bacterial phenotypes cited above 
has put into question the effectiveness of these antibiotics against S. aureus [1, 18, 19]. These 
changes in susceptibility seem to be related to the difficulty of resolving cases of S. aureus infec-
tion, leading to increased mortality of patients [20]. Altered host-pathogen interaction due to 
hVISA strains may change the course of the infection to worst prognostic for the patient. In a 
macrophage model of infection, hVISA/VISA strains showed increased capsule and reduced 
protein A (SpA, a protein surface cell), associated with reduced NF-κB activation and reduced 
TNF-α and IL-1β expression [21]. The persistent infections associated with hVISA/VISA strains 
can be a result of changes in host-pathogen interactions that culminate in attenuated host 
immune response [14].
2. Mechanisms for daptomycin resistance associated to modifications in 
cell membrane of the Staphylococcus aureus
A few years ago, antibiotic therapy using DAP to treat MRSA infections appeared to be a 
good choice; however, there are reports in the literature about bacterial strains with resistance 
to daptomycin (DAP-R) and with intermediary resistance (DAP-I) [19, 22]. S. aureus DAP-R 
infection has been associated with endocarditis and abscesses; it is characterized by high con-
centration of microorganisms in infected area with oral administration of low doses of DAP 
(i.e., ≤ 6 mg/kg/day) [23, 24]. In addition, it was observed the emergence of DAP non-suscep-
tible S. aureus phenotypes in a patient with persistent VISA bacteremia [1]. The resistant phe-
notypes of VISA strains have developed an increased DAP resistance during therapy [25, 26]. 
Besides, it could be associated with the previous use of vancomycin [27]. DAP-I mechanisms 
in S. aureus have not yet been elucidated completely, but a possible predominant phenom-
enon for the appearance of this phenotype would be an increase repulsion of DAP molecules 
of the surface cell. This modification is generally associated with an overall net charge change 
on the cell surface (for a more positive charge) [23].
The lysyl-phosphatidylglycerol (Lys-PG) is an important membrane lipid in bacteria, more 
common in Gram-positive cells [28]. The Lys-PG is incorporated into the microbial cell mem-
brane by the activity of the multiple peptide resistance factor (MprF) gene product (encoded 
by the mprF/fmtC gene). The MprF is a bifunctional protein composed by C-terminal part 
responsible by synthesize of the Lys-PG and the N-terminal hydrophobic protein domain is 
essential for efficient translocation of Lys-PG from the inner to the outer leaflet of the cyto-
plasmic membrane bacteria [28, 29].
The MprF protein catalyzes the modification of the negatively charged in phosphatidylglycerol 
(PG) with l-lysine and translocation of Lys-PG from the inside to the outside of the cell mem-
brane leaflet [30]. MprF proteins in S. aureus encompass a lysyl-phosphatidylglycerol synthase 
and a Lys-PG flippase domain, responsible for aiding the movement of phospholipid mol-
ecules between the two leaflets in cell membrane (“flip-flop” transition). Moreover, in S. aureus 
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the Lys-PG flippase and synthase in the MprF can understand two different proteins fused 
with distinct functional subunits [29].
The neutralization of the cell membrane surface leads to MprF triggered by bacterial resis-
tance to cationic antimicrobial peptides (CAMPs) [31]. MprF was first described as a viru-
lence factor of S. aureus by Peschel et al. [32], analyzing a mutant strain observed for MprF 
gene, which was unable to modify phosphatidylglycerol with l-lysine, was considerably 
faster killed by human neutrophils and exhibited an attenuated virulence in mice. This study 
indicated a key role of MprF for the resistance to defensins and cathelicidins (secreted pep-
tides in host mucosal) and implied a higher pathogenicity of S. aureus. Interestingly, MprF is 
involved in the development of DAP-R in S. aureus [33]. These observations related to cells 
with DAP-R prolife take into account several factors. Among these are mechanisms that can 
interfere with the balance in incorporation of the PG into membrane. Also, it was verified that 
the co-expression of the alanyl-PG (Ala-PG) synthase with flippase domains of Lys-PG syn-
thesizing MprF proteins led to a wild-type level of daptomycin susceptibility, indicating that 
Ala-PG can also protect bacterial membrane against DAP [33]. Moreover, the incorporation of 
the point mutations leading to amino acid exchanges in the MprF proteins of S. aureus strains 
leads to a decreased susceptibility to daptomycin [34].
Several hypotheses have been raised about the interference mechanisms of a mutant gene for the 
MprF protein in the dynamics of PG synthesis in S. aureus. It is considered that the biophysicist 
repulsion process of DAP molecules from the bacterial surface would be assigned to an increased 
PG incorporation by ΔmprF strain with singly point-mutated mprF gene (mprF
S295L
 or mprF
T345A
) 
[35]. More recently, it was noted that the decrease in susceptibility to DAP in some mutant strains 
for the MprF gene was the result of the critical effects caused by PG poor incorporation, resulting 
in failures in the oligomerization in the cell membrane, which compromise its antibacterial activ-
ity [23]. In addition, the possibility of antibiotic repulsion (such as DAP) triggered by the increase 
in positive charge can be seen in some S. aureus strains with a significant increase in cell wall thick-
ness. These strains exhibit increased MICs for drug antibiotic and VISA-DAP-R phenotype [1].
3. Mechanisms for vancomycin resistance associated to modifications in 
cell envelope of the Staphylococcus aureus
The resistance mechanisms for both VISA and hVISA appear to have common features. 
However, it is always observed in patterns that distinguish them from vancomycin-susceptible 
Staphylococcus aureus (VSSA). Although the gene expression of hVISA or VISA during expo-
sure to vancomycin denotes some patterns, subtle differences in the contribution of transcripts 
of these two phenotypes are found. One basic evidence regarding decrease in susceptibility is 
related to the cell wall thickening in bacterial cells. This process seems to initiate with the acqui-
sition of a reduced autolysis caused by downregulation of autolysin genes, such as atl/lytM 
[1]. A thickened cell wall has been highlighted as a characteristic phenotype commonly found 
in clinical VISA. This feature is intimately associated with peptidoglycan-clogging theory that 
explains vancomycin resistance by passage delay of antibiotic molecules across the thickened 
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peptidoglycan layers [18]. Punctual mutations by genetic manipulation in S. aureus strains that 
could lead to cell wall thickening were investigated thoroughly. However, these studies did 
not conclude that active point mutations involving genes of regulatory systems, autolysins 
and major catalytic enzymes could be involved in the appearance of VISA phenotypes [36, 37].
Studies conducted on gene transcription analysis showed that after exposure of DAP, the cells 
exhibit a regulation of the cell wall “stimulon,” similar to that observed in response to vanco-
mycin [1, 38]. Comparison of DAP-I and DAP-S. aureus strain pairs, which are located in the 
genes that have been associated with VISA phenotype, indicated that the genes involved in the 
synthesis and/or homeostasis of the cell wall play an important role in the resistance to vanco-
mycin observed to DAP strains [39].
Signal transduction mediated by two-component systems (TCSs)YycFG or sensor histidine 
kinase WalK (also called WalRK) is a regulatory system of two essential components of cell 
wall synthesis and homeostasis, which has also been implicated in DAP-R and VISA/VSSA 
cell phenotypes [1, 40]. Members of the two-component regulatory system WalK/WalR that 
regulate genes are involved in autolysis, biofilm formation and cell wall metabolism [1]. WalK 
functions as a sensor protein kinase, which is autophosphorylated at a histidine residue and 
transfers its phosphate group to walk [40]. The impacts of the single substitutions in either 
WalR or WalK, dramatically change the bacterial cell physiology, with significant reductions 
in autolytic activity and increases in cell wall thickness linked to the insertion of WalR or WalK 
alleles from the VISA strain into vancomycin-susceptible S. aureus (VSSA).
The impacts of the single substitutions in either WalR or WalK dramatic changes the cell bacte-
rial physiology, with significant reductions in autolytic activity and increases in cell wall thick-
ness linked to the introduction of the walR or walk allele from the VISA strain into the room fully 
vancomycin-susceptible S. aureus (VSSA). Vancomycin-intermediate S. aureus (VISA) is gener-
ated from vancomycin S. aureus sensible by multiple spontaneous mutations in two-component 
regulatory systems as standing for vancomycin resistance-associated sensor/regulator (VraSR) 
and inducible by cationic antimicrobial peptides (CAMPs), which could be important for bacte-
rial cells in resisting the harmful effects of CAMPs and possibly other antimicrobial agents [41].
The assessment of the effects of mutations directed at specific targets, which are responsible 
for the metabolism of the cell wall in S. aureus, indicated that the synergistic mutations (dou-
ble mutation) might have a more significant effect on the appearance of the VISA phenotype. 
Recently, it was observed that a deletion mutation in genes of the two-component regulatory 
system walRK (synonyms: vicRK and yycFG) might result in an increased resistance to vancomy-
cin and appearance of VISA phenotype from the S. aureus LR5P1-V3 strain. On the other hand, 
LR5P1 strain with double mutation (walK*clpP*) exhibited a thickened cell wall, slow growth and 
decreased autolytic activity [37]. Similarly, Hu et al. [42], also studying the  participation of point 
mutation in WalK (G223D) gene in S. aureus MW2 (community-acquired  methicillin-resistant), 
reported a decreased expression of genes associated with the cell wall metabolism, decreased 
autolytic activity and a reduced vancomycin susceptibility. In addition, the electrophoretic 
mobility shift assay (EMSA) indicated that WalK (G223D)-phosphorylated WalR had a reduced 
capacity to bind the atlA promoter. The atlA promoter is one of the component potential mem-
bers of the WalK/WalR regulon and is involved in cell wall metabolism in S. aureus.
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The ATP-dependent Clp protease (ClpP) consists of two heptameric rings and belongs to the 
family of serine peptidases [43]. ClpP plays an essential role in the degradation of pathogen 
cell wall but also in the regulation of their virulence [44]. The ClpP components in S. aureus are 
responsible for initiating physiological adaptive responses against different  external pressures, 
including extreme changes in temperature, osmolarity and oxidative stress [45]. In addition, the 
ClpP protease presented chaperone-like functions, recognizing and refolding misfolded pro-
teins accumulated or aggregated proteins in the cell, consequently participates in the cell enve-
lope turnover in microbial cells [46, 47].
In various pathogenic microorganisms, such as Listeria monocytogenes, Streptococcus pneu-
moniae and S. aureus, ClpP proteases have been identified in in vivo expression studies as 
an important virulence factor [44, 48, 49]. Knockout studies of the clpP ATP-dependent gene 
in S. aureus, followed by global transcriptional analysis using DNA microarray technology, 
showed that the loss of clpP leads to complete derepression of transcription of the CtsR gene 
(or yacG, a polypeptide transcriptional regulator). The ClpP proteins are regulated by the 
CtsR heat-shock repressor controlled by HRCA (heat-inducible chaperone, a heat-shock regu-
lon) and a partial derepression of genes involved in response to oxidative stress and DNA 
repair system SOS response pathway. Moreover, the expression of genes whose products 
are involved in autolysis of microbial cells was unregulated. This culminated in a dramatic 
increase in autolysis processes in S. aureus ΔclpP mutant [46]. In addition, other observations 
on the effect of the mutation identified in clpP system in S. aureus LR5P1-V3 strain indicated 
that deregulation is a new mechanism, which can lead to resistance to vancomycin. It was 
observed that the LR5P1-V3 mutant, derived from N315LR5P1, exhibited increased resistance 
to vancomycin, as MIC values rose from 1 to 8 μg/mL [37].
Recently, a genetic evaluation of vancomycin-intermediate S. aureus (VISA) isolated from the 
same patient at different times tightly corroborates an association of this phenotype with evi-
dence mutations in the novel class of genes, encoding LPXTG motif-containing cell wall-anchor-
ing proteins. These proteins contain an LPXTG sequence motif at their C-terminus, which is a 
cleavage signal that leads to the covalent binding of the proteins to the cell wall [50]. The presence 
of covalently bound LPXTG proteins has been shown to contribute to the regular cross-linked 
structure of the cell wall and anchoring of surface proteins to the peptidoglycan layer [51]. It is 
hypothesized that the origin of the VISA phenotype may be also related to mutations in the genes 
encoding LPXTG-associated proteins, leading to an aberrant peptidoglycan structure [50]. This 
new architecture would provide false binding sites for vancomycin, thus reducing the perme-
ation of this antibiotic in to the cell wall [50]. Mutations evidenced in the anchor domain LPXTG 
family proteins indicate that the phenotype VISA can have a reduced susceptibility to vanco-
mycin in vivo resulting from spontaneous or induced mutations of little-known character [52].
4. Mechanisms resistant to β-lactam antibiotics associated to penicillin-
binding protein in Staphylococcus aureus
With regard to β-lactam antibiotics, one mechanism-conditioned resistance to these antibiotics, 
mainly to methicillin and others related drugs, is the expression of penicillin-binding protein 
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modified (PBP2s). The PBP2 is a bifunctional protein produced by S. aureus and has binding 
specificity to β-lactam antibiotics. This protein presented a functional transpeptidase domain 
and carboxypeptidase domain; it is directly linked to the cell wall metabolism in bacteria [53]. In 
S. aureus, both PBPs and (PBP2) are membrane-associated proteins that  catalyze the final step of 
peptidoglycan biosynthesis. The transpeptidase and carboxypeptidase activities of PBPs occur 
at the D-Ala-D-Ala terminus of a peptidoglycan precursor containing N-acetylglucosamine 
and N-acetyl-muramic acid L-Ala-D-Glu-L-Lys-D-Ala-D-Ala (pentapeptide chain) [53].
The β-lactam antibiotics inhibit PBPs by competing with the precursor [undecaprenyl-pyro-
phosphoryl-MurNAc-(pentapeptide)] for binding to the active site of the enzyme. PBP2s 
enzymes are associated with decreased bacterial susceptibility to oral cephalosporins and 
recently, they have been implicated in the emergence of the “MRSA superbugs” [54]. One 
of the most worrisome evidence on MRSA is related to high mortality rates among infected 
patients. It is estimated that for MRSA patients, the mortality rate is two to three times higher 
than for patients infected with S. aureus susceptibly strains [55].
In methicillin-resistant S. aureus strains (MRSA), the enzymatic function can be replaced 
by PBP2 and PBP2s, proteins  encoded by the mecA gene, which act as substitutes for the 
transpeptidase [56]. The mecA gene is present on the staphylococcal cassette chromosome 
(SCC mec), a genomic island in staphylococci and other Gram-positive bacteria that encode 
methicillin resistance. Its mobile nature allows it to become widespread among microorgan-
isms [57]. Generally, in susceptible S. aureus cells, the vancomycin molecules bind on the 
C-terminal D-Ala-D-Ala, thereby inhibiting the catalytic reactions of the transglycosylation 
and transpeptidation, mediated by PBPs. Moreover, PBP2 also plays an important role in the 
resistance in MRSA; it is related to expression of high-level resistance to vancomycin [58]. This 
resistance profile is an associated expression of VanA operon, one complex genic in S. aureus 
and Enterococcus species designated as vancomycin-resistant enterococci (VRE) [59]. The vanA 
operon was acquired by VRSA from serving of the transposon Tn1546 residing on a conjugal 
plasmid; possibly, its origin is related to a transfer of the genetic element by association with 
Enterococcus faecalis in the same niche located in the host [60].
5. The cell-wall-stress stimulon response in Staphylococcus aureus
Some antibiotics related to cell wall biogenesis and its stability can influence gene expression 
and produce a cell-wall-stress stimulon (CWSS) in the S. aureus cells. The oxacillin antibiot-
ics, widely used until recently against S. aureus infections, appear to interfere in transcription 
of genes required for the synthesis of peptidoglycan in the bacterial cells. Analysis of the 
 dynamics of gene expression and proteomic studies using GeneChipsTM approach hypoth-
esized on an upregulation for some proteins and transcription factors involved in cell wall 
metabolism and response to stress. The same experimental approach that indicated the main 
influence of amoxicillin during cell exposure is related to increased expression of genes 
encoding involved in cell wall metabolism, including pbpB, Vras and Murz genes. This pat-
tern of transcriptional response can represent the signature of a stimulon cell wall induced in 
response to antibiotics, which interfere with the synthesis and structure of the cell wall [61].
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Recently, by using a reporter gene system based on a highly sensitive luciferase fused with 
tcaA and sa0908 genes, it was demonstrated that gene expression in S. aureus occurs in dif-
ferent kinetic patterns [62]. The tcaA and sa0908 genes relate to encoding a membrane pro-
tein related to signature resistance to glycopeptide antibiotics and encoding protein for the 
cell envelope (member of the LytR-CpsA-Psr family), respectively. These patterns were 
determined from observations of the fluorescence intensity during growth of S. aureus (sus-
ceptible strain BB255) in the presence of various antibiotics at subinhibitory and inhibitory 
concentrations. From their results, it was possible to establish that all drugs tested induced 
the CWSS and that the induction patterns varied according to the drug. One of the hypoth-
eses raised in this study would be that the standard kinetics observed could perhaps be 
related to the specificity or antibiotic mechanism action. These findings are based on fluo-
rescence results obtained for different drug groups such as tunicamycin, flavomycin, oxacil-
lin and fosfomycin, which presented high levels of maximal induction (RLU > 40,000); and 
daptomycin and lysostaphin exhibiting fluorescence indices below 10,000. Moreover, some 
antibiotics such as fosfomycin and D-cycloserine showed a lag-phase induction for all tested 
concentrations of about 30 and 10 min, respectively. Possibly, these antibiotics act in the 
early stages of peptidoglycan synthesis, which could be linked to delays in the induction 
CWSS in the S. aureus.
6. Conclusion
Multiple mechanisms contribute to the increased antimicrobial resistance in S. aureus, cul-
minating in a more robust cellular adaptation against antibiotics that act on the synthesis 
of components of the cell envelope. These multiple mechanisms of adaptation in S. aureus 
include heteroresistance or mutational events, make the bacteria to evolve from a suscep-
tible strain in to a resistant clone; thus significantly interfering with the bacterial response 
to antibiotics. Finally, further knowledge of these mechanisms may considerably impact 
the development of new drugs designed to specific targets in the microbial cell.
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